P-134 Expression of constitutively activated EGFRvIII in non-small cell lung cancer

Okamoto, Isamu; Kenyon, Lawrence C.; Emlet, David R.; Godwin, Andrew K.; Mori, Takeshi; Yoshioka, Masakazu; Sasaki, Jiichiro; Suga, Moritaka; Matsumoto, Mitsuhiro; Wong, Albert J.

doi:10.1016/s0169-5002(03)92103-9

Cited by 34 publications

(46 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This variant is characterized by the deletion of exons 2-7 that prevents ligand binding but confers constitutively active kinase activity to the receptor [103]. Decreased response to therapy with cisplatin and cetuximab was reported in head and neck SQCCs (HNSCCs) harboring this variant [104].…”

Section: Egfrmentioning

confidence: 99%

Genomics of Squamous Cell Lung Cancer

2013

View full text Add to dashboard Cite

show abstract

Section: Egfrmentioning

confidence: 99%

Genomics of Squamous Cell Lung Cancer

2013

View full text Add to dashboard Cite

show abstract

“…EGFRvIII is a constitutively activated truncated variant of the EGFR, which has been shown to increase tumorigenicity (Nagane et al, 2001). EGFRvIII was first identified in a subset of gliomas and has since been found in some non-small-cell lung carcinomas (Okamoto et al, 2003) and breast carcinomas (Rae et al, 2004), but not on normal cells. mAbs specific for this variant form of EGFR but unreactive with the wild-type EGFR have been reported (Reist et al, 1995;Wikstrand et al, 1995;Archer et al, 1999;Beers et al, 2000;Modjtahedi et al, 2003;Omidfar et al, 2004) and advanced development of this mutant receptor as a target is implemented.…”

Section: Naked Antibodiesmentioning

confidence: 99%

Novel antibodies as anticancer agents

2007

View full text Add to dashboard Cite

In recent years antibodies, whether generated by traditional hybridoma technology or by recombinant DNA strategies, have evolved from Paul Ehrlich's 'magic bullets' to a modern age 'guided missile'. In the recent years of immunologic research, we are witnessing development in the fields of antigen screening and protein engineering in order to create specific anticancer remedies. The developments in the field of recombinant DNA, protein engineering and cancer biology have let us gain insight into many cancer-related mechanisms. Moreover, novel techniques have facilitated tools allowing unique distinction between malignantly transformed cells, and regular ones. This understanding has paved the way for the rational design of a new age of pharmaceuticals: monoclonal antibodies and their fragments. Antibodies can select antigens on both a specific and a high-affinity account, and further implementation of these qualities is used to target cancer cells by specifically identifying exogenous antigens of cancer cell populations. The structure of the antibody provides plasticity resonating from its functional sites. This review will screen some of the many novel antibodies and antibody-based approaches that are being currently developed for clinical applications as the new generation of anticancer agents.

show abstract

“…[19][20][21][22] EGFRvIII is also a possible target of TKIs, and revealing the presence of EGFRvIII mutation in NSCLC is thus considered clinically relevant. 22 However, EGFRvIII has not been investigated in NSCLC as intensively as EGFR TKD mutations.…”

mentioning

confidence: 99%

Abnormalities of epidermal growth factor receptor in lung squamous‐cell carcinomas, adenosquamous carcinomas, and large‐cell carcinomas

Ohtsuka

Ohnìshì

Fujiwara

et al. 2007

Cancer

View full text Add to dashboard Cite

We tested the hypothesis that C57BL/6J mice will model human metabolic interactions between dl‐methylphenidate (MPH) and ethanol, placing an emphasis on the MPH transdermal system (MTS). Specifically, we asked: (1) will ethanol increase d‐MPH biological concentrations, (2) will MTS facilitate the systemic bioavailability of l‐MPH, and (3) will l‐MPH enantioselectively interact with ethanol to yield l‐ethylphenidate (l‐EPH)? Mice were dosed with MTS (¼ of a 12.5 cm2 patch on shaved skin) or a comparable oral dl‐MPH dose (7.5 mg/kg), with or without ethanol (3.0 g/kg), and then placed in metabolic cages for 3 h. MPH and EPH isomer concentrations in blood, brain, and urine were analyzed by gas chromatographic–mass spectrometry monitoring of N‐(S)‐prolylpiperidyl fragments. As in humans, MTS greatly facilitated the absorption of l‐MPH in this mouse strain. Similarly, ethanol led to the enantioselective formation of l‐EPH and to an elevation in d‐MPH concentrations with both MTS and oral MPH. Although only guarded comparisons between MTS and oral MPH can be made due to route‐dependent drug absorption rate differences, MTS was associated with significant MPH–ethanol interactions. Ethanol‐mediated increases in circulating concentrations of d‐MPH carry toxicological and abuse liability implications should this animal model hold for ethanol‐consuming attention‐deficit hyperactivity disorder patients or coabusers. © 2011 Wiley‐Liss, Inc. and the American Pharmacists Association J Pharm Sci 100:2966–2978, 2011

show abstract

P-134 Expression of constitutively activated EGFRvIII in non-small cell lung cancer

Cited by 34 publications

References 10 publications

Genomics of Squamous Cell Lung Cancer

Genomics of Squamous Cell Lung Cancer

Novel antibodies as anticancer agents

Abnormalities of epidermal growth factor receptor in lung squamous‐cell carcinomas, adenosquamous carcinomas, and large‐cell carcinomas

Contact Info

Product

Resources

About